Tag: Human Papillomavirus (HPV)
American Cancer Society Updates HPV Vaccination Guidelines
Vaccination should be routinely offered at age 9 to 12 years; catch-up vaccination recommended through age 26
Artificial Intelligence Provides Benefit for Cervical Cancer Screening
Automated dual-stained slide evaluation reduces number of colposcopies versus current standards
Multilevel Interventions May Boost HPV Vaccination Rates
Improvements in initiation and completion extend beyond conclusion of the intervention
Race, Insurance Status Linked to Lower Cancer Survival
Reduced survival seen in HPV-associated head and neck cancer for nonwhite, uninsured patients
Single Dose of HPV Vaccine May Cut Preinvasive Cervical Disease
Risk for preinvasive cervical disease decreased with one, two, three vaccine doses at age 15 to 19 years
Whether HPV Vaccination Will Prevent Cervical Cancer Unclear
Review highlights limitations of trial design; additional research needed to address uncertainties
Vaccine Program Recovery Difficult After Public Scares
Misinformation is threat to resilience of vaccination programs globally, authors say
Mortality Risk in Oropharynx Cancer Varies Based on HPV Status
Patients with OPC with HPV-negative tumors have increased risk for head and neck cancer mortality
CDC: Young Adults Who Ever Received HPV Vaccine on the Rise
2013 to 2018 saw increase in percentage having received one or more doses, recommended number of doses
Routine HPV Testing May Be Warranted for Sinonasal Cancers
HPV-positive sinonasal squamous cell carcinoma associated with improved overall survival
